BioSpace6h
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still ...
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research ...
Royalty Pharma price target raised to $39 from $38 at BofA
BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The ...
Sen-Jam Pharma launches Phase II trial of hangover prevention treatment
A previous pilot study examining the company’s SJP-001 compound found it was able to cut hangover symptoms such as headaches, ...